First- or Second-Line Treatment of Metastatic or Locally Advanced Uterine Leiomyosarcoma with Fixed-Dose Rate Gemcitabine and Docetaxel

This is a clinical practice guideline for the systemic first- or second-line treatment of metastatic or locally advanced uterine leiomyosarcoma. The guide facilitates the safe and effective clinical use of fixed-dose rate gemcitabine and docetaxel. Treatment outcomes are non-curative and look to prolong progression-free survival and overall survival.